Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trump has Covid 19
Trump tested positive for Covid 19
Art Hill says the last 4 days of the month and the first 4 days of the next month is called the turn of the month. It more profitable then playing the entire year .
So you have four more days
What if it breaks 23.42 ?
Back to 19 ?
That wa phases 1 and 2
JNJ just started phase 3 so they will not have results for three months
So you do not know either !
FREE FROM ART HILL 9/27/20
https://trendinvestorpro.com/2-equity-etfs-holding-up-well-in-september/print/
When Will the flu pill be ready?
When will flu pill be ready?
Working with JNJ on a pill for the FLU
May be a good buy ?
Just started phase 3 today September 25
Vaccine needs just one shot
Vaccine can be kept at refrigerator temperature
EPS equals 5.63
Dividend yield is 2.57%
Will buy any of 9 vaccine stocks if RSI(14) BELOW 30
Alerts are set.
SOLD TQQQ AFTER HOURS
GDRX
Sorry. This chart is for me.
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=1401935,3&cmd=show&disp=e
BOUGHT TQQQ
Free Prescription Coupons - Official GoodRx® Site
https://www.goodrx.com/prescription/coupons
How is it able to offer the discounts ?
Lot's of TV
could be a winner ?
big jump in price
IPO today
SOLD TQQQ
What is your best quest at this time there will be FDA approval ?
Or do you have any guess ?
Can you trust the Washington Post ????
FDA poised to announce tougher standards for a covid-19 vaccine that make it unlikely one will be cleared by Election Day
Washington POST
I BUY TQQQ LONG only using charts.
BOUGHT TQQQ
SEP 21 SPX UP =5 DOWN =4 STILL BULLISH
While major international pharmaceutical companies from the Western world are fully committed to producing an FDA and EUA-approved vaccine, there are competitors in other parts of the world looking to provide our planet with a vaccine more quickly than initially thought. What does this mean for pharmaceutical like AstraZeneca ($AZN), Moderna ($MRNA) and Pfizer ($PFE) and others, who go through the entire COVID-19 vaccine development?
China and Russia appear to be increasing their lead over Western competition as news has come out once again this weekend that these countries have begun a massive rollout of vaccine candidates. This process is already underway before clinical trials are completed, presenting an unexpectedly complex geopolitical challenge to the United States. Last week, China’s Sinopharm announced that in the upcoming weeks one of the emergency doses of a vaccine candidate will be shipped to the United Arab Emirates. The ally of the United States is not the only country to enter into negotiations with China. As a matter of fact, several countries in the Middle East have signed agreements with Eastern pharmaceutical companies who promise to
Middle East have signed agreements with Eastern pharmaceutical companies who promise to come up with a vaccine within the coming weeks
India, Brazil, Mexico and Kazakhstan have now agreed to use Sputnik V vaccines in emergency situations. The same goes for Egypt, Jordan and Beirut and a trial with Sinopharm. Egypt had previously signed an agreement with AstraZeneca stating that the British-Swedish pharmaceutical company will provide 30 million doses of the vaccine after FDA approval. Three days after AstraZeneca announced that the Phase 3-clinical trial was being halted due to a complication with a patient, Egypt also decided to start a partnership with Sinopharm.
Is the interest of the Middle East and other Eastern countries a threat to pharmaceuticals from the Western World? So far this does not seem to be the case, even if China and Russia do a massive rollout of their vaccine candidates in early 2021. Zhou Song, one of the directors of Sinopharm, previously indicated that the company expects an initial production of 300 million doses per year. At two doses per person, that would cover 10 procent of the Chinese population. The Russian Direct Investment Fund said it expects to have produced 30 million doses in Russia by the end of 2020, an equivalent to nearly 20 percent of the population.
With that, a vast majority of the world’s population remains awaiting an approved COVID-19 vaccine, which can be answered by the major Western pharmaceutical companies. Recently, a worldwide survey found that one in three people still has doubts about the production, motives and quality of the vaccine, a percentage that will rise sharply with the introduction of Chinese and Russian vaccines in Western countries. This means that previous criticism from doctors to stop the production and research of American and European vaccin-candidates does not seem relevant. There’s no need to worry about the economic consequences with China and Russia taking an irresponsible shortcut.
Good move
Only one month away from OCT 23 when the FDA will looking at the data for the COVID 19 VACCINE.
BUY if they hit RSI 14 = 30